I. E. Smith

2.3k citations

35 papers · 1.9k · 1 hit paper · h-index 18

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Metal complexes synthesis and properties
Cancer Research top 5%
- Breast Cancer Treatment Studies

Papers in

Oncology 13
- Lung Cancer Research Studies 5
- Cancer Treatment and Pharmacology 3
- Peptidase Inhibition and Analysis 3
Pulmonary and Respiratory Medicine 11

Co-authors: Mitch Dowsett (6 shared papers)T.J. Powles (2 shared papers)Alwynne Tidy (1 shared paper)S. Ashley (1 shared paper)S.J. Harland (3 shared papers)A. Hilary Calvert (2 shared papers)Eve Wiltshaw (2 shared papers)Kenneth R. Harrap (2 shared papers)
Journals: The Lancet (8 papers)Cancer Chemotherapy and Pharmacology (4 papers)Annals of Oncology (3 papers)British Journal of Cancer (3 papers)Radiotherapy and Oncology (2 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

I. E. Smith

35 papers receiving 1.8k citations

I. E. Smith's Hit Papers

align trajectories log scale

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II 1982 · 447 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

1982 Cancer Chemotherapy and Pharmacology

Peers

Countries citing papers authored by I. E. Smith

Since Specialization

Citations

This map shows the geographic impact of I. E. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. E. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. E. Smith more than expected).

Fields of papers citing papers by I. E. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. E. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. E. Smith. The network helps show where I. E. Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside I. E. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with I. E. Smith Line = papers co-authored together I. E. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II Cancer Chemotherapy and Pharmacology ·A. Hilary Calvert, S.J. Harland, David R. Newell, Zahid Hussain Siddik, A C Jones, T J McElwain, S. Raju, Eve Wiltshaw Hit paper breakdown →	1982	447
2	Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial JNCI Journal of the National Cancer Institute ·T.J. Powles, S. Ashley, Alwynne Tidy, I. E. Smith, Mitch Dowsett	2007	352
3	Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. PubMed ·S R Johnston, Gloria Saccani‐Jotti, I. E. Smith, Janine Salter, Jacqueline C. Newby, M J Coppen, Steve R. Ebbs, Mitch Dowsett	1995	265
4	PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMA The Lancet ·B.M. Bryant, H. Thomas Ford, Michael Jarman, I. E. Smith	1980	123
5	Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. PubMed ·A A Daffada, S R Johnston, I. E. Smith, Simone I. DETRE, Nicholas C. King, Mitchell Dowsett	1995	99
6	Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology ·R P Kedar, David Owen Cosgrove, I. E. Smith, Janine Mansi, Jeffrey C. Bamber	1994	82
7	Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial I. E. Smith, Mitch Dowsett	2003	60
8	Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma Cancer Chemotherapy and Pharmacology ·EdwardK. Mbidde, S.J. Harland, A. Hilary Calvert, I. E. Smith	1986	53
9	Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy Lung Cancer ·Courtney Lucas, Bridget Anne Robinson, P J Hoskin, John R. Yarnold, I. E. Smith, H. Thomas Ford	1987	52
10	Prognostic significance of serum prolactin levels in advanced breast cancer British Journal of Cancer ·Mitch Dowsett, Gail McGarrick, Adrian L. Harris, Raoul Charles Coombes, I. E. Smith, S.L. Jeffcoate	1983	44
11	Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy Cancer Chemotherapy and Pharmacology ·S.J.P. Van Belle, Mariet M. de Planque, I. E. Smith, A.T. van Oosterom, T. J. Schoemaker, Wilfried DeNeve, J. Gordon McVie	1986	40
12	Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. BMJ ·Jane E. Anderson, Jasmine Hunt, I. E. Smith	1981	39
13	Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer Annals of Oncology ·Mónica Arnedos, S. Drury, Maria Afentakis, Roger A’Hern, Margaret Hills, Janine Salter, I. E. Smith, Jorge Sergio Reis-Filho	2014	38
14	Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer British Journal of Cancer ·R. Stuart‐Harris, David William Hedley, Ian W. Taylor, Arnold Levene, I. E. Smith	1985	37
15	Endocrine Changes Associated with Relapse in Advanced Breast Cancer Patients on Aminoglutethimide Therapy The Journal of Clinical Endocrinology & Metabolism ·Mitch Dowsett, Adrian L. Harris, I. E. Smith, S.L. Jeffcoate	1984	32
16	SYMPTOMATIC HYPOCALCAEMIA AFTER TREATMENT WITH HIGH-DOSE AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE The Lancet ·DuncanI. Jodrell, TimJ. Iveson, I. E. Smith	1987	32
17	ENCEPHALOPATHY WITH RAPID INFUSION IFOSFAMIDE/MESNA The Lancet ·Timothy John Perren, Rachel Turner, I. E. Smith	1987	26
18	JM8 Development and Clinical Projects A. Hilary Calvert, S.J. Harland, Kenneth R. Harrap, Eve Wiltshaw, I. E. Smith	1984	19
19	Small Cell Carcinoma of the Prostate: Implications for Management British Journal of Urology ·Fiona Adshead, Alexander de Graeff, Janine Mansi, Dorothea Thomas, I. E. Smith	1991	13
20	Tamoxifen-induced tumour regression associated with dermatomyositis. BMJ ·Adrian L. Harris, I. E. Smith, Michael L. Snaith	1982	11

About I. E. Smith

I. E. Smith is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Cancer Research and Epidemiology, having authored 35 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (5 papers), Estrogen and related hormone effects (5 papers), Chemotherapy-induced organ toxicity mitigation (5 papers), Neuroendocrine Tumor Research Advances (5 papers), Cancer Treatment and Pharmacology (3 papers), Peptidase Inhibition and Analysis (3 papers), Breast Cancer Treatment Studies (2 papers) and Chemotherapy-related skin toxicity (2 papers). The work is most often cited by research in Oncology (857 citations), Cancer Research (361 citations), Genetics (553 citations), Pathology and Forensic Medicine (309 citations) and Pulmonary and Respiratory Medicine (306 citations). I. E. Smith has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Mitch Dowsett, T.J. Powles, Alwynne Tidy, S. Ashley, S.J. Harland, A. Hilary Calvert, Eve Wiltshaw, Kenneth R. Harrap, T J McElwain and David R. Newell. Their work appears in journals such as The Lancet, Cancer Chemotherapy and Pharmacology, Annals of Oncology, British Journal of Cancer and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

I. E. Smith

Impact in

Papers in i

In The Last Decade

I. E. Smith

I. E. Smith's Hit Papers

Peers

Countries citing papers authored by I. E. Smith

Fields of papers citing papers by I. E. Smith

All Works

About I. E. Smith

Explore authors with similar magnitude of impact

Papers in